NASDAQ:XLRN - Acceleron Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $148.21
  • Forecasted Upside: 19.08 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
▼ -3.83 (-2.99%)

This chart shows the closing price for XLRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acceleron Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XLRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XLRN

Analyst Price Target is $148.21
▲ +19.08% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Acceleron Pharma in the last 3 months. The average price target is $148.21, with a high forecast of $200.00 and a low forecast of $99.00. The average price target represents a 19.08% upside from the last price of $124.47.

This chart shows the closing price for XLRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 investment analysts is to buy stock in Acceleron Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021SVB LeerinkReiterated RatingHoldHigh
3/29/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00High
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$148.00N/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$148.00High
3/22/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00 ➝ $132.00N/A
3/11/2021Wolfe ResearchInitiated CoverageOutperform$200.00Medium
3/1/2021CitigroupBoost Price TargetBuy$137.00 ➝ $171.00Low
2/26/2021Piper SandlerBoost Price TargetOverweight$130.00 ➝ $143.00Low
2/26/2021Morgan StanleyBoost Price TargetOverweight$135.00 ➝ $145.00High
2/26/2021SVB LeerinkBoost Price TargetOutperform$138.00 ➝ $148.00Low
1/29/2021JPMorgan Chase & Co.Boost Price TargetOverweight$133.00 ➝ $153.00Low
1/19/2021Raymond JamesBoost Price TargetStrong-Buy$155.00 ➝ $160.00High
1/19/2021HC WainwrightBoost Price TargetBuy$148.00 ➝ $168.00High
12/21/2020BarclaysBoost Price TargetOverweight$133.00 ➝ $150.00Medium
12/16/2020Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $135.00Low
11/16/2020OppenheimerBoost Price TargetOutperform$120.00 ➝ $131.00Low
11/6/2020Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $130.00High
11/6/2020SVB LeerinkBoost Price TargetOutperform$134.00 ➝ $138.00High
11/6/2020HC WainwrightBoost Price TargetBuy$137.00 ➝ $148.00High
10/13/2020Morgan StanleyBoost Price TargetOverweight$123.00 ➝ $125.00Low
9/29/2020HC WainwrightReiterated RatingBuyLow
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$155.00Medium
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$134.00 ➝ $135.00High
8/7/2020SVB LeerinkBoost Price TargetOutperform$132.00 ➝ $134.00High
7/15/2020Morgan StanleyBoost Price TargetOverweight$122.00 ➝ $123.00Low
7/7/2020Piper SandlerLower Price TargetOverweight$135.00 ➝ $130.00Low
6/26/2020SVB LeerinkBoost Price TargetOutperform$127.00 ➝ $132.00High
6/25/2020CowenBoost Price TargetOutperform$121.00 ➝ $140.00High
6/25/2020Royal Bank of CanadaBoost Price TargetSector Perform$72.00 ➝ $99.00High
6/25/2020Credit Suisse GroupBoost Price TargetOutperform$123.00 ➝ $134.00Medium
6/25/2020OppenheimerReiterated RatingBuy$115.00 ➝ $120.00High
6/2/2020CitigroupBoost Price TargetBuy$136.00 ➝ $137.00High
5/12/2020SVB LeerinkBoost Price Target$104.00 ➝ $127.00High
5/12/2020BarclaysReiterated RatingBuy$116.00High
5/12/2020JPMorgan Chase & Co.Boost Price TargetOverweight$108.00 ➝ $118.00High
5/12/2020OppenheimerBoost Price TargetOutperform$112.00 ➝ $115.00High
5/8/2020Credit Suisse GroupBoost Price TargetOutperform$99.00 ➝ $123.00Low
5/4/2020HC WainwrightReiterated RatingBuy$137.00High
4/6/2020Piper SandlerReiterated RatingBuy$135.00Medium
4/6/2020Credit Suisse GroupReiterated RatingBuy$99.00Medium
4/6/2020OppenheimerBoost Price TargetOutperform$108.00 ➝ $112.00Low
4/6/2020HC WainwrightBoost Price TargetBuy$128.00 ➝ $137.00Medium
4/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$73.00High
3/10/2020HC WainwrightLower Price TargetBuy$129.00 ➝ $128.00High
3/2/2020CitigroupLower Price TargetBuy$138.00 ➝ $136.00Low
2/27/2020BarclaysInitiated CoverageOverweight$107.00Medium
2/18/2020HC WainwrightBoost Price TargetBuy$90.00 ➝ $129.00Low
2/11/2020OppenheimerBoost Price TargetOutperform$79.00 ➝ $112.00Medium
2/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$52.00 ➝ $122.00Low
1/28/2020OppenheimerBoost Price Target$57.00 ➝ $79.00High
1/28/2020CowenBoost Price Target$78.00 ➝ $109.00High
1/28/2020Piper SandlerBoost Price TargetOverweight$73.00 ➝ $135.00High
1/28/2020The Goldman Sachs GroupReiterated RatingNeutral$47.00 ➝ $81.00High
1/28/2020Royal Bank of CanadaBoost Price TargetSector Perform$72.00High
1/28/2020Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $99.00High
1/28/2020CitigroupBoost Price TargetBuy ➝ Buy$75.00 ➝ $138.00High
1/27/2020Royal Bank of CanadaReiterated RatingHold$47.00Medium
1/22/2020CitigroupBoost Price TargetBuy$52.00 ➝ $75.00High
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$48.00 ➝ $52.00High
12/10/2019HC WainwrightInitiated CoverageBuy$88.00Low
11/11/2019HC WainwrightReiterated RatingBuy$68.00 ➝ $88.00Medium
11/6/2019CowenReiterated RatingBuyLow
10/21/2019Piper Jaffray CompaniesSet Price TargetBuy$71.00Low
10/13/2019CowenReiterated RatingBuyMedium
10/11/2019Morgan StanleyLower Price TargetEqual Weight$52.00 ➝ $48.00Low
9/17/2019SVB LeerinkDropped CoverageBuy$55.00N/A
9/17/2019OppenheimerSet Price TargetBuy$58.00Low
9/17/2019HC WainwrightReiterated RatingBuy$68.00High
9/17/2019CitigroupLower Price TargetBuy ➝ Buy$61.00 ➝ $52.00High
9/6/2019HC WainwrightReiterated RatingBuy$69.00Medium
8/26/2019Credit Suisse GroupSet Price TargetBuy$58.00Low
8/6/2019JPMorgan Chase & Co.Lower Price TargetOverweight$61.00 ➝ $58.00Medium
7/15/2019Morgan StanleySet Price TargetHold$53.00Medium
6/4/2019HC WainwrightReiterated RatingBuy$69.00High
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$54.00 ➝ $54.00Medium
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$66.00Low
5/13/2019HC WainwrightBoost Price TargetBuy$66.00 ➝ $69.00High
5/12/2019CowenReiterated RatingBuy$78.00High
5/10/2019Piper Jaffray CompaniesReiterated RatingOverweight$71.00 ➝ $74.00Low
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$54.00 ➝ $45.00Medium
4/22/2019CIBCReiterated RatingOutperform ➝ OutperformLow
4/22/2019OppenheimerReiterated RatingOutperformLow
2/28/2019HC WainwrightReiterated RatingBuy ➝ Buy$72.00 ➝ $67.00High
2/25/2019CowenInitiated CoverageOutperform$78.00High
12/3/2018HC WainwrightReiterated RatingBuy$72.00Low
9/17/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$52.00 ➝ $75.00High
9/10/2018Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$55.00Medium
8/3/2018HC WainwrightReiterated RatingBuy$73.00Medium
7/23/2018HC WainwrightReiterated RatingBuy$74.00Medium
7/13/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$50.00Low
7/12/2018Royal Bank of CanadaReiterated RatingHold$48.00Medium
7/10/2018HC WainwrightBoost Price TargetBuy$74.00High
7/10/2018UBS GroupBoost Price TargetBuy$62.00High
7/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$32.00High
6/29/2018Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$55.00 ➝ $60.00High
6/29/2018Piper Jaffray CompaniesBoost Price TargetOverweight$55.00High
6/29/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$21.00 ➝ $40.00High
5/9/2018Credit Suisse GroupSet Price TargetBuy$55.00High
5/9/2018HC WainwrightBoost Price TargetBuy$69.00Low
4/26/2018HC WainwrightReiterated RatingBuy$62.00Medium
3/2/2018Credit Suisse GroupReiterated RatingBuy$55.00High
3/1/2018CitigroupBoost Price TargetBuy ➝ Positive$44.00 ➝ $63.00High
2/28/2018BarclaysBoost Price TargetOverweight ➝ Overweight$50.00 ➝ $54.00High
2/28/2018HC WainwrightReiterated RatingBuy$62.00High
2/28/2018Piper Jaffray CompaniesBoost Price TargetOverweight$53.00High
2/26/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$33.00High
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$55.00Medium
1/8/2018OppenheimerReiterated RatingHoldMedium
12/11/2017OppenheimerReiterated RatingHoldMedium
12/11/2017HC WainwrightReiterated RatingBuy$62.00Medium
11/14/2017OppenheimerReiterated RatingHoldN/A
11/14/2017Credit Suisse GroupSet Price TargetBuy$35.00 ➝ $51.00N/A
11/7/2017HC WainwrightBoost Price TargetBuy ➝ Buy$57.00 ➝ $62.00N/A
11/2/2017Royal Bank of CanadaReiterated RatingHoldN/A
10/12/2017HC WainwrightInitiated CoverageBuy ➝ Buy$57.00N/A
9/20/2017OppenheimerReiterated RatingHoldHigh
9/20/2017BarclaysBoost Price TargetOverweight$42.00 ➝ $50.00High
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$44.00Low
9/12/2017UBS GroupReiterated RatingBuy$36.00 ➝ $50.00High
9/5/2017OppenheimerReiterated RatingHoldLow
8/5/2017Credit Suisse GroupSet Price TargetBuy$35.00Low
8/4/2017CitigroupBoost Price TargetBuy$44.00High
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$40.00Medium
7/4/2017Credit Suisse GroupReiterated RatingBuy$46.00Medium
6/26/2017Piper Jaffray CompaniesBoost Price TargetOverweight$32.00 ➝ $40.00High
6/14/2017Nomura InstinetReiterated RatingBuy$58.00Low
6/13/2017(FBRC)Set Price TargetBuy$63.00High
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 ➝ $42.00High
6/13/2017CIBCDowngradeOutperform ➝ Market PerformLow
6/13/2017OppenheimerReiterated RatingOutperform ➝ Market PerformHigh
6/1/2017OppenheimerSet Price TargetBuy$40.00High
5/18/2017(FBRC)Reiterated RatingBuyHigh
5/17/2017The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$20.00High
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$46.00Low
4/8/2017(FBRC)Reiterated RatingBuyMedium
4/6/2017Credit Suisse GroupReiterated RatingBuy$46.00Low
3/26/2017(FBRC)Reiterated RatingBuyMedium
3/14/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$33.00High
3/9/2017UBS GroupInitiated CoverageBuy ➝ Buy$36.00N/A
3/2/2017(FBRC)Set Price TargetBuy$63.00N/A
3/2/2017CitigroupUpgradeNeutral ➝ Buy$40.00 ➝ $36.00N/A
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$58.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
3/1/2017OppenheimerSet Price TargetBuy$44.00 ➝ $40.00N/A
12/25/2016OppenheimerInitiated CoverageBuy$44.00N/A
12/13/2016OppenheimerInitiated CoverageOutperform$44.00N/A
12/1/2016SVB LeerinkSet Price TargetBuy$50.00N/A
10/7/2016SVB LeerinkReiterated RatingOutperformN/A
9/29/2016CitigroupInitiated CoverageNeutral$40.00N/A
9/28/2016(FBRC)Reiterated RatingBuyN/A
9/28/2016Credit Suisse GroupReiterated RatingBuy$42.00N/A
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/A
8/5/2016(FBRC)Reiterated RatingBuy$63.00N/A
8/5/2016Morgan StanleyReiterated RatingBuy$58.00N/A
7/10/2016Credit Suisse GroupReiterated RatingBuyN/A
6/29/2016Morgan StanleyReiterated RatingOverweightN/A
(Data available from 6/23/2016 forward)
Acceleron Pharma logo
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $124.47
Low: $123.75
High: $128.46

50 Day Range

MA: $125.48
Low: $116.50
High: $133.44

52 Week Range

Now: $124.47
Low: $85.58
High: $146.15


289,927 shs

Average Volume

346,346 shs

Market Capitalization

$7.56 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Acceleron Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Acceleron Pharma in the last year: Barclays PLC, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for XLRN.

What is the current price target for Acceleron Pharma?

14 Wall Street analysts have set twelve-month price targets for Acceleron Pharma in the last year. Their average twelve-month price target is $148.21, suggesting a possible upside of 19.1%. Wolfe Research has the highest price target set, predicting XLRN will reach $200.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $99.00 for Acceleron Pharma in the next year.
View the latest price targets for XLRN.

What is the current consensus analyst rating for Acceleron Pharma?

Acceleron Pharma currently has 3 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XLRN will outperform the market and that investors should add to their positions of Acceleron Pharma.
View the latest ratings for XLRN.

What other companies compete with Acceleron Pharma?

How do I contact Acceleron Pharma's investor relations team?

Acceleron Pharma's physical mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is 617-649-9200 and its investor relations email address is [email protected] The official website for Acceleron Pharma is